Document Detail

Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients.
MedLine Citation:
PMID:  22874106     Owner:  NLM     Status:  In-Data-Review    
Background: Ferumoxytol is a unique intravenous (i.v.) iron therapy. This report examines factors affecting hemoglobin response to i.v. ferumoxytol, and the relationship between hematologic parameters, concomitant erythropoiesis-stimulating agents (ESA), and adverse events (AEs) in nondialysis CKD patients. Methods: A series of post-hoc efficacy and safety analyses were performed using pooled data from two identically designed Phase III studies in 608 nondialysis CKD patients randomized to receive two 510 mg i.v. injections of ferumoxytol within 5 ± 3 days versus oral iron. Results: Ferumoxytol resulted in a significant increase in hemoglobin in the presence and absence of ESA, and across a range of baseline hemoglobin, transferrin saturation, ferritin, and reticulocyte hemoglobin content levels. Adverse event rates with ferumoxytol were similar across quartiles of change in hemoglobin; there were no trends suggesting an increased rate of cardiovascular AEs with higher maximum achieved hemoglobin or faster rate of hemoglobin rise. There was no meaningful difference in the rate of AEs, serious AEs, and cardiovascular AEs between patients receiving or not receiving ESA. Conclusions: These analyses add to the knowledge of predictors of response and safety outcomes associated with i.v. iron therapy in nondialysis CKD patients.
Steven Fishbane; W Kline Bolton; Wolfgang C Winkelmayer; William Strauss; Zhu Li; Brian J G Pereira
Related Documents :
9135516 - The helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dys...
391656 - Cephalic phase of gastric secretion in healthy subjects and duodenal ulcer patients: ro...
438346 - Gastin cells and fasting gastrin levels in duodenal ulcer patients: a quantitative stud...
22874106 - Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidne...
9525756 - Evaluation of altered myocardial high energy phosphate metabolism in patients on mainte...
14668616 - Role of functional plasminogen-activator-inhibitor-1 4g/5g promoter polymorphism in sus...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  78     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  181-8     Citation Subset:  IM    
Hofstra North Shore LIJ, School of Medicine, Great Neck, NY, University of Virginia Health System, Charlottesville, VA, Stanford University School of Medicine, Palo Alto, CA, and AMAG Pharmaceuticals, Inc., Lexington, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Apolipoprotein E and kidney function in older adults.
Next Document:  Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal ane...